The profit problem in antibiotic R&D

@article{Nathan2005ThePP,
  title={The profit problem in antibiotic R\&D},
  author={Carl F. Nathan and Fred Marvin Goldberg},
  journal={Nature Reviews Drug Discovery},
  year={2005},
  volume={4},
  pages={887-891}
}
Economists, a biomedical researcher and a business executive have formulated three contrasting proposals to address the shortfall in antibiotic R&D. Their proposals, which emphasize advance purchase contracts, not-for-profit research, and tax incentives, respectively, share some features with provisions in bills pending before the US Congress that could potentially reshape the R&D landscape for this essential class of drugs. 

Topics from this paper

Tools to Incentivize Research and Development for Pharmaceuticals
  • Kishen Anand, Luca Maini
  • Journal of Student Research
  • 2021
This article is a review of the current state of pull mechanisms and differential pricing in relation to incentivizing pharmaceutical research and development. In many developing nations, there is aExpand
Policies and Incentives for Promoting Innovation in Antibiotic Research
TLDR
This book analyses many proposed policies and incentive mechanisms and sheds light on the key issues that will help policy-makers reach informed, concrete decisions on how to avert this potential public health crisis. Expand
Aligning pharmaceutical innovation with medical need
  • C. Nathan
  • Business, Medicine
  • Nature Medicine
  • 2007
TLDR
A fundamental solution to these problems requires aligning three basic processes—innovation, incentive and access—so that they become mutually reinforcing. Expand
Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
TLDR
Using resistance data to estimate global revenues, it is demonstrated that the combined effects of these incentives are unlikely to rekindle investment in antibiotics and significant efforts should be made to test the insurance model as one route to stimulate investment in novel antibiotics. Expand
Public funding of clinical-stage antibiotic development in the United States and European Union.
TLDR
This article describes government programs that directly fund late-stage clinical development of antibiotics, including the antibiotics and their targeted pathogens and clinical indications, as well as program mechanisms for project eligibility, selection, governance, funding, and IP management. Expand
Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
  • A. White
  • Business, Medicine
  • The Journal of antimicrobial chemotherapy
  • 2011
TLDR
The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed. Expand
All EU hands to the EU pumps: the Science Academies of Europe (EASAC) recommend strong support of research to tackle antibacterial resistance.
  • I. Gyssens
  • Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2008
TLDR
Multidisciplinary input from the fields of finance, law, marketing, sociology and psychology will inform a broad agenda for change at the regulatory, academic and commercial levels and identify new options for novel anti-infective research and development. Expand
The crisis of no new antibiotics--what is the way forward?
  • L. Piddock
  • Medicine
  • The Lancet. Infectious diseases
  • 2012
TLDR
This initiative aims to strengthen and enhance academic-industrial partnerships, bring about revision of costly and laborious processes of licensing and regulation of new antibiotics, and address the economics of antimicrobial drugs (cost of use vs profit). Expand
Research and development of antibiotics: insights from patents and citation network
TLDR
Patents and patent citations are broadly believed to be powerful tools in representing the technology advances and capturing technology flows and the inter-relationship between patented technologies on antibiotics is further revealed. Expand
Drug Resistance as a Global Health Policy Priority
Drug resistance is a major impediment to the successful treatment of HIV/AIDS, tuberculosis, and malaria – the three diseases prioritized for urgent action in developing countries – as well asExpand
...
1
2
3
4
5
...

References

SHOWING 1-7 OF 7 REFERENCES
Why is big Pharma getting out of antibacterial drug discovery?
  • S. Projan
  • Biology, Medicine
  • Current opinion in microbiology
  • 2003
TLDR
Since the advent of the antibiotic era in the late 1940s the cost and complexities of drug discovery and development have shifted the investment equation away from the development of drugs targeting short course therapies for acute diseases and towards long-term treatment of chronic conditions. Expand
The antibiotic pipeline--challenges, costs, and values.
  • R. Wenzel
  • Medicine
  • The New England journal of medicine
  • 2004
Dr. Richard P. Wenzel examines the dramatic reduction in the number of pharmaceutical companies engaged in the discovery of antiinfective agents.
Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases
TLDR
It is concluded that a commitment to purchasing vaccines could develop within low-income countries and that developing countries now have the right to produce drugs protected by the patent holder and to grant compulsory licenses to home manufacturers through this agreement. Expand
Antibiotics at the crossroads
Are we making the right choices to bring new drugs to the marketplace?
Antibacterial resistance worldwide: causes, challenges and responses
The optimism of the early period of antimicrobial discovery has been tempered by the emergence of bacterial strains with resistance to these therapeutics. Today, clinically important bacteria areExpand
Citing human threat , U . S . bans a poultry drug
  • New York Times A
  • 2005
causes, challenges and responses
  • Nature Med. 10, S122–S129
  • 2004